66892-37-3

Usage

Chemical structure

A complex structure containing a spiro compound, an imidazolidine ring, and a dione group.

Methoxy group position

A methoxy group is present at the 6' position, contributing to its chemical properties.

Spiro compound

The compound features a spiro structure, which is a central atom or group connected to two other rings.

Imidazolidine ring

A five-membered ring structure with two nitrogen atoms and three carbon atoms.

Dione group

A functional group with two carbonyl groups (C=O) within the same molecule.

Potential applications

The compound has potential uses in pharmaceuticals and organic chemistry due to its unique structure and reactivity.

Synthetic chemistry target

The compound's structure makes it an interesting target for synthetic chemistry research.

Medicinal chemistry research

Its properties and potential uses may yield valuable insights into applications in medicinal chemistry.

Further study and exploration

More research is needed to fully understand the properties and potential applications of 2',3'-dihydro-6'-methoxyspiro-2,5-dione.

Upstream product

• 13623-25-1 6-methoxy-2,3-dihydro-1H-inden-1-one 
• 151-50-8 potassium cyanide 

Downstream Products

• 144646-26-4 1-benzamido-2,3-dihydro-6-methoxy-1H-indene-1-carboxylic acid 
• 144732-04-7 N^2.2-<(S)-1-benzamido-2,3-dihydro-6-methoxy-1H-indene-1-carbonyl>-L-phenylalanyl-L-phenylalanine N^1.3,N^1.3-(tetramethylene)amide 
• 144646-50-4 N^2.2-<(R)-1-benzamido-2,3-dihydro-6-methoxy-1H-indene-1-carbonyl>-L-phenylalanyl-L-phenylalanine N^1.3,N^1.3-(tetramethylene)amide 
• 144733-25-5 methyl 1-benzamido-2,3-dihydro-6-methoxy-1H-indene-1-carboxylate 

Relevant academic research and scientific papers

Spiro hydantoin aldose reductase inhibitors

Sorbitol formation from glucose, catalyzed by the enzyme aldose reductase, is believed to play a role in the development of certain chronic complications of diabetes mellitus. Spiro hydantoin derived from five- and six-membered ketones fused to an aromatic ring or ring system inhibit aldose reductase isolated from calf lens. In vivo these compounds are potent inhibitors of sorbitol formation in sciatic nerves of streptozotocinized rats. Optimum in vivo activity is reached in spiro hydantoins derived from 6-halogenated 2,3-dihydro-4H-1-benzopyran-4-ones (4-chromanones). In 2,4-dihydro-6-fluorospirol[4H-1-benzopyran-4,4'-imidazolidine]-2',5'- ione, the activity resides exclusively in the 4S isomer, compound 115 (CP-45,634, USAN: sorbinil). This compound is currently being used to test, in humans, the value of aldose reductase inhibitors in the therapy of diabetic complications.

Hydantoin derivatives as therapeutic agents

A series of spiro-hydantoin compounds has been prepared by condensing the appropriate carbonyl ring compound, such as the corresponding 1-indanone, 1-tetralone, 4-chromanone, thiochroman-4-one, 7,8-dihydroquinolin-5(6H)-one, 6,7-dihydropyrindin-5(5H)-one, thiondane-3-one-1,1-dioxide and 4-oxoisothiochroman-2,2-dioxide, respectively, with potassium cyanide and ammonium carbonate. The resulting hydantoin derivatives are found to be useful in preventing or alleviating chronic diabetic complications. Preferred member compounds include spiro-[imidazolidine-4,1'-indan]-2,5-dione, 6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione, 6-chloro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione, 6,7-dichloro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione, 6,8-dichloro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione, 6'-fluoro-spiro-[imidazolidine-4,4'-thiochroman]-2,5-dione and 6',7'-dichloro-spiro-[imidazolidine-4,4'-thiochroman]-2,5-dione.